Articles

Lenalidomide before and after ASCT for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial

Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK;
Perlmutter Cancer Center, NYU Langone Health, New York, USA;
The Institute of Cancer Research & The Royal Marsden Hospital NHS Foundation Trust, London, UK;
Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, UK;
Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, UK;
Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, UK;
Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, UK;
Kings College Hospital NHS Foundation Trust, London, UK;
Heart of England NHS Foundation Trust, Birmingham, UK;
Leicester Royal Infirmary, Leicester, UK;
Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, UK;
University Hospital of North Midlands, Stoke-on-Trent, UK;
East Kent Hospitals University NHS Foundation Trust, Canterbury, UK;
Derby Teaching Hospitals NHS Foundation Trust, Derby, UK;
Worcestershire Acute Hospitals NHS Trust, Worcester, UK;
University Hospital Southampton NHS Foundation Trust, Southampton, UK;
Section of Experimental Haematology, Leeds Institute of Cancer & Pathology, University of Leeds, UK;
Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, UK;
The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, London, UK;
Clinical Immunology, School of Immunity and Infection, University of Birmingham, UK;
St James's University Hospital, Haematological Malignancy Diagnostic Service (HMDS), Leeds, UK
Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, UK;
Perlmutter Cancer Center, NYU Langone Health, New York, USA;
Haematologica Early view Jun 4, 2020 https://doi.org/10.3324/haematol.2020.247130